Impact of Isotretinoin in Different Doses on Quality of Life

Last updated: March 30, 2022
Sponsor: Assiut University
Overall Status: Active - Not Recruiting

Phase

4

Condition

Acne

Rash

Scalp Disorders

Treatment

N/A

Clinical Study ID

NCT05316675
aila
  • Ages 12-45
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The Cardiff Acne Disability Index is a short five-item questionnaire derived from the longer Acne Disability Index.It is designed for use in teenagers and young adults with acne. It is self explanatory and can be simply handed to the patient who is asked to complete it without the need for detailed explanation( .Abdelrazik etal., 2021).

.

Eligibility Criteria

Inclusion

Inclusion Criteria: Patients with clinically diagnosed acne vulgaris older than 18 years of age

Exclusion

Exclusion Criteria: Patients having personal or family history of hyperlipidemia. Pregnancy and lactation.Newly married female desiring to get pregnant or using temporary method of contraception. Patients with a history suggestive of any psychic disturbance -

Study Design

Total Participants: 100
Study Start date:
December 01, 2022
Estimated Completion Date:
December 31, 2024

Study Description

Lower doses of isotretinoin can be effective in terms of cost and decreasing systemic side effects. Therefore, other regimens may be used instead of daily conventional dose as alternate, pulse and low doses of oral isotretinoin in acne vulgaris( Agarwal et al., 2011).

To study the impact of different protocols of systemic isotretinoin in acne treatment on quality of life among egyptian patients using Cardiff Acne Disability Index (CADI) and dermatology life quality index (DLQI)questionnaires.

To assess validity and reliability of the translated Arabic version of CADI. To compare the clinical efficacy and tolerability of different protocols of systemic isotretinoin in acne treatment.